MacroGenics Stock Price. Everything You Need To Know About The MacroGenics Stock!
MacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 357 full-time employees. The company went IPO on 2013-10-10. The company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. The company is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. The company is also developing various other programs.
MacroGenics Stock Price. Everything You Need To Know About The MacroGenics Stock! performance
- Employees 357
- Company HQ Rockville
- Website https://www.macrogenics.com/
- MGNX Asset Type Common Stock
- MGNX Market Capitalization 910.9M
- Earnings Per Share -0.15
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Are you a retail investor from Malaysia, Thailand, Indonesia, or Vietnam looking to expand your investment portfolio? Look no further than MacroGenics, a promising stock that you can consider. As a content marketing expert at Zorion, I understand the importance of making informed decisions about your investments. MacroGenics is a reputable biopharmaceutical company, known for its innovative research and development in the field of cancer treatments. With their cutting-edge technologies and extensive pipeline of potential therapies, investing in MacroGenics can be a lucrative opportunity. Visit Zorion’s platform to access investment insights, recommendations, and educational materials to guide you in your investment journey. Start investing in MacroGenics today and witness the growth potential firsthand.
